EcoDrugPlus

Mitogen-Activated Protein Kinase Kinase Kinase 13

Ensembl ID : ENSXMAG00000015692
Gene Symbol: MAP3K13
3 Cross references
198 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 5

Ensembl ID : ENSXMAG00000016278
Gene Symbol: MAP3K5
3 Cross references
203 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 8

Ensembl ID : ENSXMAG00000022332
Gene Symbol: MAP3K8
3 Cross references
200 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 9

Ensembl ID : ENSXMAG00000014520
Gene Symbol: MAP3K9
3 Cross references
193 Possible Orthologues:

Monoglyceride Lipase

Ensembl ID : ENSXMAG00000009052
Gene Symbol: MGLL
3 Cross references
208 Possible Orthologues:

Motilin Receptor

Ensembl ID : ENSXMAG00000028025
Gene Symbol: MLNR
3 Cross references
174 Possible Orthologues:

Muscarinic Acetylcholine Receptor M2-Like

Ensembl ID : ENSXMAG00000017689
Gene Symbol: LOC102225705
3 Cross references
195 Possible Orthologues:

Muscarinic Acetylcholine Receptor M4-Like

Ensembl ID : ENSXMAG00000009655
Gene Symbol: LOC102235242
2 Cross references
184 Possible Orthologues:

Muscarinic Acetylcholine Receptor M5

Ensembl ID : ENSXMAG00000019711
Gene Symbol: LOC102222626
3 Cross references
189 Possible Orthologues:

Natriuretic Peptide Receptor 2

Ensembl ID : ENSXMAG00000008594
Gene Symbol: NPR2
2 Cross references
185 Possible Orthologues:

Natriuretic Peptide Receptor 2

Ensembl ID : ENSXMAG00000001184
Gene Symbol: NPR2
3 Cross references
191 Possible Orthologues:

Natriuretic Peptide Receptor 3

Ensembl ID : ENSXMAG00000023378
Gene Symbol: NPR3
3 Cross references
207 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).